Emicizumab use in infancy: A survey of United States Pediatric Hemophilia Treatment Center Medical Directors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Emicizumab use in infancy: A survey of United States Pediatric Hemophilia Treatment Center Medical Directors

Published:2024-02-29 Issue:3 Volume:30 Page:848-851
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Cohen Clay T.¹^ORCID,Tarango Cristina²^ORCID,Powers Jacquelyn M.¹

Affiliation:

1. Division of Hematology/Oncology Department of Pediatrics Baylor College of Medicine Texas Children's Cancer and Hematology Center Houston Texas USA

2. Division of Hematology Cancer and Blood Diseases Institute Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati Ohio USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14959

Reference10 articles.

1. Emicizumab Prophylaxis in Hemophilia A with Inhibitors

2. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

3. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

4. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial

5. Recommendation on the use and management of EMICIZUMABKXWH(HEMLIBRA®) for hemophilia A with and without inhibitors. National Hemophilia Foundation;2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP